By Fineline Cube 
UK-based AstraZeneca (AZ, NASDAQ: AZN) announced plans to invest $50 billion in the United States by 2030 to expand its pharmaceutical manufacturing and R&D footprint. This initiative supports the company’s goal of reaching $80 billion in total revenue by 2030, with approximately 50% expected to come from the U.S. market.
Virginia API Facility
Central to this investment is the construction of a new multibillion-dollar active pharmaceutical ingredient (API) facility in Virginia—the largest single manufacturing investment in the company’s global history. The site will produce key ingredients for AstraZeneca’s innovative portfolio in metabolism and weight management, including oral GLP-1, baxdrostat, oral PCSK9, and small molecule combination therapies. The facility will support diverse modalities such as small molecules, peptides, and oligonucleotides, and will incorporate AI, automation, and data analytics to enhance manufacturing efficiency.
Expansion Across Multiple States
In addition to the Virginia site, AstraZeneca will expand R&D and manufacturing facilities in Maryland, Massachusetts, California, Indiana, and Texas, further strengthening its U.S. operations.
Current US Operations and Economic Impact
Currently, AstraZeneca operates 19 R&D, manufacturing, and commercial facilities across the United States, employing over 18,000 people and supporting more than 92,000 direct and indirect jobs. In 2024, the company contributed $5 billion directly to the U.S. economy, generating an estimated total economic impact of $20 billion.-Fineline Info & Tech